GlaxoSmithKline plc operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares GlaxoSmithKline plc with three other companies in this sector in UNITED STATES : Abbvie Inc (2020 sales of $45.80 billion of which 100% was pharmaceutical products), Sanofi S.A. ($42.87 billion of which 69% was Pharmaceuticals), and Bristol-Myers Squibb Company ($42.52 billion of which 28% was Prioritized Brands-Revlimid).

Sales Analysis. During the year ended December of 2020, sales at GlaxoSmithKline plc were $44.07 billion. This is an increase of 2.1% versus 2019, when the company's sales were $43.18 billion. This was the fifth consecutive year of sales increases at GlaxoSmithKline plc (and since 2015, sales have increased a total of 21%). Sales of Consumer Healthcare saw an increase that was more than double the company's growth rate: sales were up 12.7% in 2020, from $11.51 billion to $12.97 billion. Not all segments of GlaxoSmithKline plc experienced an increase in sales in 2020: sales of Unallocated fell 41.1% to $36.19 million. (However, this segment's sales were only a very small portion of the company's overall sales). GlaxoSmithKline plc also experienced decreases in sales in Pharmaceuticals (down 1.8% to $22.04 billion) and Vaccines (down 1.4% to $9.02 billion) .